Showing 3981-3990 of 7132 results for "".
- FDA Gives Nod to First Particulate Placental Extracellular Matrix Medical Device for Wound Managementhttps://practicaldermatology.com/news/fda-gives-nod-to-first-particulate-placental-extracellular-matrix-medical-device-for-wound-management/2461574/The U.S. Food and Drug Administration cleared Convatec’s InnovaMatrix PD particulate placental extracellular matrix medical device for wound management. The InnovaMatrix PD medical device joins Convatec’s existing InnovaMatrix AC product as the first and only next-gener
- Dove Partners with LinkedIn in Effort to Help End Race-Based Hair Discrimination in the Workplacehttps://practicaldermatology.com/news/dove-partners-with-linkedin-in-effort-to-help-end-race-based-hair-discrimination-in-the-workplace/2461566/In an effort to help pass “The CROWN Act,” which aims to end race-based hair discrimination, Dove announced it is partnering with LinkedIn. The NEW CROWN 2023 Workplace Research Study, co-commissioned by Dove and LinkedIn, found that black women's hair is 2.5x more
- Neauvia Scores CE Marking Under the European Union’s New MDR for Facial Dermal Filler Linehttps://practicaldermatology.com/news/neauvia-scores-ce-marking-under-the-european-unions-new-mdr-for-facial-dermal-filler-line/2461564/Neauvia scored CE marking under the European Union’s new MDR (Medical Device Regulation) for its range of facial dermal fillers products, making it the first medical aesthetics business to receive such certification in Europe. The new regulation aims to create ‘a robus
- Relief Therapeutics Enrolls First Patients in Proof-of-Concept Trial of Epidermolysis Bullosa Treatmenthttps://practicaldermatology.com/news/relief-therapeutics-enrolls-first-patients-in-proof-of-concept-trial-of-epidermolysis-bullosa-treatment/2461563/Relief Therapeutics announced the first three patients have been enrolled in a proof-of-concept, investigator-initiated study to evaluate RLF-TD011 as a treatment for epidermolysis bullosa (EB). The primary aim of the study will be to assess changes in the skin microbiome (Staphylococcu
- Eye on the AD Pipeline: Dermavant Completes Enrollment of Phase 3 Trials of VTAMA in Adults and Children with ADhttps://practicaldermatology.com/news/eye-on-the-ad-pipeline-dermavant-completes-enrollment-of-phase-3-trials-of-vtama-in-adults-and-children-with-ad/2461561/Dermavant Sciences has completed patient enrollment in its ADORING 1 and 2 Phase 3 clinical trials of VTAMA (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children as young as 2 years old. VTAMA cream is a novel, aryl hydrocarbon receptor agonist
- Experts React to Approval of Pfizer’s CIBINQO for Teens With Refractory ADhttps://practicaldermatology.com/news/fda-oks-pfizers-cibinqo-for-teens-with-refractory-ad/2461560/The US FDA has approved a supplemental New Drug Application (sNDA) for CIBINQO (abrocitinib, Pfizer). This move expands the drug's indication to include adolescents (12 to < 18 years) with refractory, moderate to severe atopic dermatitis (AD) whose disease is not adequately contr
- LEO Pharma Announces Positive Phase 3 Trial Results for Delgocitinib Cream in Adults With Chronic Hand Eczema (CHE)https://practicaldermatology.com/news/leo-pharma-announces-positive-phase-3-trial-results-for-delgocitinib-cream-in-adults-with-chronic-hand-eczema-che/2461556/LEO Pharma announced positive results of the DELTA 2 trial, the second of two pivotal phase 3 clinical trials evaluating delgocitinib cream, an investigational topical pan-Janus kinase (JAK)-inhibitor for the potential treatment of adults with moderate to severe chronic hand eczema (CHE).
- Study: Six Percent of Children Have Eczema Symptoms Worldwidehttps://practicaldermatology.com/news/study-six-percent-of-children-have-eczema-symptoms-worldwide/2461550/About 6% of children and adolescents have some form of eczema, according to New research published in Clinical & Experimental Allergy. In addition, 0.6% of children and 1.1% of adolescents across the g
- Escient Pharmaceuticals Receives FDA IND Clearance to Start Phase 1 Study of EP262https://practicaldermatology.com/news/escient-pharmaceuticals-receives-fda-ind-clearance-to-start-phase-1-study-of-ep262/2461542/The FDA has cleared Escient Pharmaceuticals’ investigational new drug (IND) application for EP262. The clearance allows the Escient to initiate a Phase 1 first-in-human study for the company’s second drug candidate to be advanced into clinical development. EP262 is a first-i
- Avero Diagnostics Launches Test for Early-Stage Melanoma Progressionhttps://practicaldermatology.com/news/avero-diagnostics-launches-test-for-early-stage-melanoma-progression/2461541/Avero Diagnostics announced the US launch of AMBLor, a laboratory test for the identification of early-stage melanomas at low risk of progression. AMBLor technology identifies the presence of two prognostic biomarker proteins, AMBRA1 and loricrin, in the skin overlying the tumor, a